An official website of the United States government
Develop and disseminate best practices for the collection, processing, and multi-omics molecular profiling of human and animal model biosamples.
2024 RFA-AG-18-014: Limited Competition: Data Coordinating Center for the Accelerating Medicines Partnership Target Discovery and Preclinical Validation Consortium AMP AD DCC (U24- Clinical Trial Not Allowed) RFA-AG-18-013: Continuation of the AMP AD Target Discovery and Preclinical Validation Consortium (U01 Clinical Trial Optional) 14.I Achieved DN 2018 AD Summit: 2F Public Private Partnerships AMP AD 2.0 Foundational Grants Biospecimen best practice guidelines for the Alzheimer's Disease Research Centers 2019
Ensure adoption of best practices across different research groups and institutions to enable harmonized analyses of data collected at the national and international level.
Summary of Key Accomplishments
The NIA-supported AD Research Centers (ADRC) network established best practices guidelines for biospecimen collection – these have been disseminated across the ADRCs network and are also available to the greater research community.
In addition, the research teams supported through the Accelerated Medicines Partnership for AD (AMP AD) and Model Organism Development & Evaluation for Late-Onset Alzheimer’s Disease (MODEL-AD) programs are establishing best practices for multi-omic data generation from human and animal models biospecimens. The data generation and analytical methods are being distributed to the research community via the NIA-supported AD Knowledge Portal.
The key accomplishments summary is current as of July 2022.